IMV Inc.

A New Class of Immunotherapies

Everyone Deserves a Long and Healthy Life 

At IMV, we believe that everyone deserves effective cancer treatments that respect patients’ quality of life. Our unique DPX technology gives us the ability to create a new class of immunotherapy that generates targeted and long-lasting immune activation with limited side effects. With this unique ability, we are dedicated to improving cancer treatment and giving everyone a chance to enjoy a long and healthy life.  

About IMV

Our DPX Platform

Our DPX Platform

A Versatile Technology That Generates a Targeted, Robust and Sustained Immune Response

Thanks to its unique “no release” delivery system, our proprietary DPX delivery platform can be formulated with peptide antigens to induce a specific, robust, and sustained immune response. IMV is leveraging this mechanism of action to generate “first-in-class” T cell therapies for patients facing cancer. In the context of infectious diseases, the DPX™ platform can also be formulated with B cell epitopes to target virus’ specific regions like spike proteins of the SARS-CoV2.

Our Lead Candidate: maveropepimut-S

Our Lead Candidate: maveropepimut-S

One Immunotherapy to Tackle Both Solid and Hematologic Tumors

Our lead asset, maveropepimut-S (DPX-Survivac), is a T cell activating immunotherapy which combines the advantages of the DPX™ platform and the cancer antigen survivin. Maveropepimut-S generates in vivo a constant flow of T cells that target cancer cells expressing survivin, a promising tumor-associated target overexpressed in a high percentage of tumor types.

About Maveropepimut-S

Latest News

Read More
Read More
Read More
View all news

Email Alerts

Stay informed and receive company updates straight to your inbox.

Sign up today
Stock Information

Stock Information

View Corporate Presentation View Investor Relations